RVRC
What one share of REVIUM Rx. holds
Pharmaceutical Preparations
We are a pre-clinical stage biopharmaceutical company focused on the development and eventual commercialization of innovative and proprietary nanoparticle-based therapies. We focus on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing effectiveness while reducing side effects.
REVIUM Rx.’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.22 |
|---|---|
| Cash and investments | $0.01 |
| Book value | $0.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$0.22 | — | — | — | $0.11 |